financetom
Business
financetom
/
Business
/
Form 8.3 - AMERICAN AXLE & MANUFACTURING HOLDINGS, INC.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - AMERICAN AXLE & MANUFACTURING HOLDINGS, INC.
Oct 15, 2025 7:34 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Verition Fund Management LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AMERICAN AXLE & MFG HOLDINGS

 

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

14 October 2025

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

Yes – the Offeree:

DOWLAIS GROUP PLC

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

USD 0.01 Common

US0240611030

Interests

 

Short positions

 

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

544,776

0.45

2,627,622

2.21

(2) Cash-settled derivatives:

72,499

0.06

419

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

612,275

0.51

2,628,041

2.21

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions)

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security: US0240611030

Purchase/ sale

Number of securities

Price per unit (USD)

USD 0.01 Common

Sale

4,700

5.29

USD 0.01 Common

Sale

38,000

5.54

USD 0.01 Common

Sale

14,400

5.60

USD 0.01 Common

Purchase

1,082

5.60

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security: US0240611030

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit (USD)

USD 0.001 Common

CFD

Reducing a long position

5,350

5.58

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

 

(c) Attachments

Class of relevant security:

USD 0.01 Common

US0240611030

Interests

 

Short positions

 

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

544,776

0.45

2,627,622

2.21

(2) Cash-settled derivatives:

72,499

0.06

419

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

612,275

0.51

2,628,041

2.21

0

Class of relevant security:

USD 0.01 Common

US0240611030

Interests

 

Short positions

 

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

544,776

0.45

2,627,622

2.21

(2) Cash-settled derivatives:

72,499

0.06

419

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

612,275

0.51

2,628,041

2.21

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Verition Fund Management LLC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Copyright 2023-2026 - www.financetom.com All Rights Reserved